DDIT3 and type 2 diabetes mellitus: In conclusion, these results suggest a novel therapeutic strategy via targeting CHOP in β cells to mitigate the development of T2D, while regulating insulin secretion and alleviating syndromes of consequent fatty liver disease (Yong et al., 2021).